06.03.2012

4000 Swiss patent applications in 2011

Despite difficult economic conditions, international patent filings under the WIPO-administered Patent Cooperation Treaty (PCT) set a new record in 2011. The number of Swiss patents grew also by 7%.

“The recovery in international patent filings that we saw in 2010 gained strength in 2011,” said WIPO Director General Francis Gurry. “This underlines the important role played by the PCT system in a world where innovation is an increasingly important feature of economic strategy. It also shows that companies have been continuing to innovate in 2011 – reassuring news in times of persistent economic uncertainty.”

Attesting to the rapid growth of the PCT system, 2011 also saw the filing of the two millionth PCT application, by US-based mobile technology company Qualcomm.

Among the top filing countries, PCT applications from China (+33.4%), Japan (+21%), Canada (+8.3%), the Republic of Korea (+8%) and the US (+8%) saw the fastest growth in 2011. European countries witnessed a mixed performance, with Switzerland (+7.3%), France (+5.8%), Germany (+5.7%) and Sweden (+4.6%) experiencing growth, and the Netherlands (-14%), Finland (-2.7%), Spain (-2.7%) and the United Kingdom (-1%) seeing declines. The large middle-income economies of the Russian Federation (+20.8%), Brazil (+17.2%) and India (+11.2%) recorded double-digit filing growth.

The US with 48,596 filings remains the largest user of the PCT system, followed by Japan (38,888), Germany (18,568) and China (16,406). Switzerland ranks 8th with nearly 4000 filings.  

More information on the WIPO website.

Industries

Interdisciplinary

Categories

Report

Subscribe Newsletter


Stay up2date!

Get the startupticker.ch App
for your Phone or your Tablet!
   

Swiss start-up turns to the Nasdaq

Last year Auris Medical raised more than CHF47 million in venture capital for further growth. This was the largest round of financing in Switzerland in 2013. The company has two drugs in development: an injection for tinnitus and a drug for hearing loss in the inner ear. The tinnitus medication has already started the third and most expensive stage of development, the phase III trial. The Basel company, which has its headquarters in Zug, intends to raise the necessary capital on the Nasdaq: the IPO should bring Auris a total of $95 million in new money.

Partners

Sponsors